PMID: 1234497Apr 1, 1975

An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man

British Journal of Clinical Pharmacology
G E MarlinP Turner


1 Oral ICI 66,082 (200 mg) or water (control treatment) were each administered to six healthy volunteers. 2 The heart rate (HR) and peak flow rate (PFR) were measured at rest and during vigorous exercise before and at intervals up to 24 h after each treatment. 3 ICI 66,082 produced significant reductions in exercise HR at all times compared with the changes after the control treatment (P less than 0.001), whereas with resting HR, corresponding significant reductions only occurred at 2,3 and 4 h (P less than 0.05). 4 Although there was no change in resting PFR, significant reductions in exercise PFR, compared with the changes after the control treatment, occurred at all times excepting at 2 h after ICI 66,082 (P less than 0.025). 5 The findings are consistent with ICI 66,082 possessing partial cardioselectivity. 6 Plasma levels and renal excretion of the drug were determined. Urinary recovery was variable which, together with the plasma concentration/effect relationships obtained, raise the possibility that ICI 66,082 is metabolized in man.


May 17, 1978·European Journal of Clinical Pharmacology·J D FitzgeraldJ McAinsh
Jan 1, 1982·European Journal of Drug Metabolism and Pharmacokinetics·W Kirch, K G Görg
Apr 1, 1977·British Journal of Clinical Pharmacology·J F GiudicelliA Berdeaux
Jul 1, 1979·British Journal of Pharmacology·J MacLagan, U M Ney
Apr 24, 1976·British Medical Journal·A P Douglas-Jones, J M Cruickshank
Aug 21, 1976·British Medical Journal·J S Vilsvik, J Schaanning
Jan 1, 1978·British Heart Journal·C RobinsonD Jewitt
Sep 30, 1976·European Journal of Clinical Pharmacology·J F De PlaenT Reybrouck
May 1, 1980·European Journal of Clinical Pharmacology·A RouxB Flouvat
Jan 1, 1977·Current Medical Research and Opinion·N K GostickN P Barmer
Jan 1, 1976·The Journal of International Medical Research·A M HarrisJ A Tweed
Dec 18, 2019·The Cochrane Database of Systematic Reviews·Sanam SafiChristian Gluud
Apr 1, 1976·The Journal of Pharmacy and Pharmacology·W C Bowman, C Raper
Jan 1, 1977·Acta Medica Scandinavica. Supplementum·J Meier
Jul 1, 1980·British Journal of Clinical Pharmacology·J F GiudicelliP L Morselli
May 1, 1978·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·P R ReevesM J Winrow


Jul 26, 1974·European Journal of Clinical Pharmacology·C R Kumana, C M Kaye
Jul 1, 1967·Lancet·D A ChamberlainJ M Sneddon
Sep 26, 1970·British Medical Journal·D J Coltart, D G Shand
Mar 1, 1972·Clinical Pharmacology and Therapeutics·C R Cleaveland, D G Shand
Nov 23, 1974·British Medical Journal·C R KumanaD M Smith
May 1, 1974·Clinical Pharmacology and Therapeutics·S G CarruthersR G Shanks
Mar 1, 1953·Journal of Applied Physiology·S ROBINSOND I MILLER
Dec 1, 1974·British Journal of Clinical Pharmacology·C M Kaye

Related Concepts

Peak Expiratory Flow Rate Measurement
Pulse Rate

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.